Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

Mediar Therapeutics has entered a global licensing agreement with Eli Lilly and Company to progress the human immunoglobulin ...

Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant ...

Eli Lilly and Company’s LLY shares declined 6.6% on Tuesday after the company lowered its sales guidance for full-year 2024 ...

Heading into fiscal 2025, CEO David Ricks said the company expects sales of weight-loss drugs will continue growing, and noted that it expects "to produce at least 60% more salable doses" of the drugs ...

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market ...

NEW YORK – Eli Lilly on Monday said it will acquire Scorpion Therapeutics' mutant-PI3Kα inhibitor STX-478 for up to $2.5 billion while Scorpion spins out a new entity to develop its non-PI3Kα assets.

US pharma major Eli Lilly is to buy the PI3Kα inhibitor program STX-478 from Scorpion Therapeutics, a private US biotech ...

US fibrosis-focused drug developer Mediar Therapeutics has entered into global licensing agreement with US pharma major Eli ...